Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.
Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses an analysis of minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL) given venetoclax (Venclexta) and obinutuzumab (Gazyva) on the CLL14 (NCT02242942).
A majority of patients on the trial were MRD negative after 6 cycles out 12. When using next-generation sequencing to detect low levels of MRD, investigators saw that a third of patients had deepened remissions between cycles 7 and 12. The extra 6 cycles of therapy deepens the MRD negativity to the 10-6 in over half of patients who had undetectable MRD at the end of treatment. Al-Sawaf says this shows there is a rationale to use all 12 cycles and the design implemented in the CLL14 trial of venetoclax monotherapy.
The investigators also looked at patients who had detectable MRD at the end of treatment on the study. Among the approximate 20 patients with detectable MRD, about half had lower levels of MRD at cycle 7 compared with at the end of treatment. If those patients continued with treatment, they would probably not achieve deeper remissions since the patients had increasing MRD levels while on treatment, according to Al-Sawaf. He says these patients could potentially benefit in the future from treatment intensification or similar strategies depending on their ultimate goal of therapy.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More